What’s in Vbi Vaccines Inc – Ordinary Shares (NASDAQ:VBIV) After Decline in Shorted Shares?

March 14, 2018 - By Louis Casey

 What’s in Vbi Vaccines Inc   Ordinary Shares (NASDAQ:VBIV) After Decline in Shorted Shares?

The stock of Vbi Vaccines Inc – Ordinary Shares (NASDAQ:VBIV) registered a decrease of 50.26% in short interest. VBIV’s total short interest was 423,000 shares in March as published by FINRA. Its down 50.26% from 850,400 shares, reported previously. With 96,000 shares average volume, it will take short sellers 4 days to cover their VBIV’s short positions. The short interest to Vbi Vaccines Inc – Ordinary Shares’s float is 1.1%.

The stock decreased 1.27% or $0.05 during the last trading session, reaching $3.89. About 65,576 shares traded. VBI Vaccines Inc. (NASDAQ:VBIV) has risen 7.87% since March 14, 2017 and is uptrending. It has underperformed by 8.83% the S&P500.

VBI Vaccines Inc., a commercial stage biopharmaceutical company, develops vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company has market cap of $156.49 million. It is developing eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines; and Lipid Particle Vaccine technology, a vaccine formulation technology that enables the thermostabilization of vaccines through a proprietary formulation and freeze-drying process. It currently has negative earnings. The firm also offers Sci-B-Vac, a third-generation hepatitis B vaccine for adults, children, and newborn infants.

VBI Vaccines Inc. (NASDAQ:VBIV) Ratings Coverage

Among 4 analysts covering VBI Vaccines (NASDAQ:VBIV), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. VBI Vaccines had 6 analyst reports since July 26, 2016 according to SRatingsIntel. The stock of VBI Vaccines Inc. (NASDAQ:VBIV) earned “Buy” rating by Laidlaw on Monday, October 10. The rating was initiated by Ladenburg Thalmann on Tuesday, July 26 with “Buy”. The stock of VBI Vaccines Inc. (NASDAQ:VBIV) has “Buy” rating given on Wednesday, November 1 by Canaccord Genuity. The stock of VBI Vaccines Inc. (NASDAQ:VBIV) earned “Buy” rating by BMO Capital Markets on Wednesday, November 15.

More notable recent VBI Vaccines Inc. (NASDAQ:VBIV) news were published by: Globenewswire.com which released: “VBI Vaccines Announces Closing of Public Offering and Concurrent Registered …” on October 31, 2017, also Benzinga.com with their article: “Exclusive: VBI Vaccines CEO Talks Pipeline, Investor Backing, Hep. B Vaccine …” published on April 03, 2017, Benzinga.com published: “VBI Vaccines Could Nearly Triple In Value On New Drug Launches, According To BMO” on November 15, 2017. More interesting news about VBI Vaccines Inc. (NASDAQ:VBIV) were released by: Globenewswire.com and their article: “VBI Vaccines Announces Voluntary Delisting from the Toronto Stock Exchange” published on March 12, 2018 as well as Benzinga.com‘s news article titled: “Meet VBI Vaccines, The Biotech Up 100% In 2017” with publication date: March 07, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: